Missed Semaglutide Dose: The Evidence-Based Protocol

The TL;DR

For once-weekly injectable semaglutide (Wegovy, Ozempic):

• Less than 5 days late: take the dose now. Resume your regular weekly schedule.
• 5 or more days late: skip it. Take your next dose on its regular day.
• More than 2 consecutive weeks missed: contact your prescriber before restarting.

For daily oral semaglutide (Rybelsus, Wegovy Oral): skip the missed dose. Take your next dose at the regular time the next morning. Never take two tablets on the same day.

The rest of this post explains why — which is worth knowing, because the rules only become intuitive once you understand the pharmacokinetics.

Why the 5-day window

The Wegovy and Ozempic prescribing information sets the cutoff at "within 5 days after the missed dose". This is the official rule from the FDA label. The underlying logic is straightforward: at 5 days post-dose, plasma concentrations of semaglutide are still well above the threshold where additional medication provides value. Beyond 5 days, levels have declined enough that adding a dose close to the next scheduled dose pushes the patient into an accidental double-dose zone.

The pharmacokinetics

Semaglutide's half-life is approximately 7 days. That means one week after injection, roughly half of the drug is still circulating. After another week, about 25% remains. This is why the medication is dosed weekly — and why missing by a day or two has negligible effect on long-term efficacy, while missing by more than a week starts to matter.

A "catch-up" dose taken 6 days after a missed injection, then another regular dose 2 days later, would mean two injections within 8 days. Because semaglutide accumulates slowly, this briefly doubles your exposure. The FDA label avoids this by capping catch-up at 5 days and defaulting to "skip" beyond that.

Why you should never double up

Doubling is tempting — "I forgot last Sunday, I'll take two this Sunday to make up." Don't. Here is what happens when you double:

• Acute GI effects spike. Nausea, vomiting, and diarrhea are dose-dependent. A double dose hits like the first day of a titration step for most patients, but at the higher level. For maintenance-dose patients, the effect can be severe.
• Dehydration risk rises. Combine vomiting and diarrhea with the delayed gastric emptying semaglutide already causes, and you're playing defense against volume depletion.
• Hypoglycemia risk rises in patients also on insulin or sulfonylureas.
• Pancreatitis risk increases in rare cases. Baseline rates are low, but doubling dose is one of the scenarios associated with elevated risk.
• You don't catch up on weight loss. Cumulative exposure matters over months, not days. Doubling one week doesn't meaningfully accelerate the trajectory.

What to do after a long gap

If you've been off semaglutide for two or more consecutive weeks, don't resume at your previous dose. Your gut has partially re-sensitized. Stepping back in at maintenance dose risks a full rerun of early-titration GI symptoms — severe nausea, vomiting, dehydration.

Contact your prescriber. The common approach is to step back one titration level for 4 weeks before advancing. For example, a patient on 2.4 mg who's been off for 3 weeks might restart at 1.7 mg for a month. This smooths the re-acclimation.

Missed oral doses (Rybelsus, Wegovy Oral)

Oral semaglutide is daily, not weekly, and the rule is different: skip the missed tablet entirely. Do not take two tablets on the same day. The daily cadence means tomorrow's dose is never far away.

There is a specific reason doubling oral doses is problematic. Rybelsus uses an absorption enhancer called SNAC that transiently alters gastric pH to protect the peptide. Absorption is already highly variable — only about 1% of an oral dose reaches the bloodstream. Taking two tablets together does not predictably produce double the plasma level; it can produce much more or much less, depending on conditions. The label therefore defaults to skip.

Sources

1. Wegovy (semaglutide) prescribing information, Section 2.3 "Missed dose". Novo Nordisk. FDA-approved label revision, 2025.
2. Ozempic (semaglutide) prescribing information, Section 2.2 "Missed dose". Novo Nordisk. FDA-approved label revision, 2025.
3. Rybelsus (semaglutide) prescribing information, Section 2.3. Novo Nordisk.
4. Hall S, et al. Pharmacokinetic modeling of semaglutide across dosing regimens. Clin Pharmacokinet. 2018;57:1535-1547.